Enfortumab vedotin in urothelial cancer: durable responses in patients who had previously received immunotherapy but were ineligible for Cisplatin in locally advanced or metastatic setting
The results from the second cohort of patients in the pivotal phase 2 single-arm clinical trial known as EV-201, were presented.
The cohort is evaluating the antibody-drug conjugate Enfortumab vedotin ( Enfortumab vedotin-ejfv; Padcev ) for patients with locally advanced or metastatic urothelial cancer who have been previously treated with a PD-1/L1 inhibitor and have not received a Platinum-containing chemotherapy and are ineligible for Cisplatin.
The results have shown a 52% objective response rate ( ORR ) [ 95% Confidence Interval ( CI ): 40.8, 62.4 ] per blinded independent central review and a median duration of response of 10.9 months.
The most frequently reported treatment-related adverse events grade 3 or greater that occurred in more than 5% of patients were: neutropenia, rash, fatigue, increased lipase, diarrhea, decreased appetite, anemia and hyperglycemia.
Enfortumab vedotin is a first-in-class antibody-drug conjugate ( ADC ) that is directed against nectin-4, a protein located on the surface of cells and highly expressed in bladder cancer.
Advanced urothelial cancer in patients who have received immunotherapy and are ineligible for Cisplatin is a particularly difficult disease to treat. Typically, these patients are frail, suffer from multiple comorbidities beyond their urothelial cancer and are not able to tolerate additional treatment beyond immunotherapy, leading many to discontinue therapy altogether.
This is the first trial to report objective responses in patients with advanced urothelial cancer who had previously received immunotherapy but were ineligible for Cisplatin in this setting due to inadequate kidney function or other conditions.
The EV-201 trial is a single-arm, pivotal phase 2 clinical trial of Enfortumab vedotin for patients with locally advanced or metastatic urothelial cancer who have been previously treated with a PD-1 or PD-L1 inhibitor, including those who have also been treated with a Platinum-containing chemotherapy ( cohort 1 ) and those who have not received a Platinum-containing chemotherapy in this setting and who are ineligible for Cisplatin ( cohort 2 ).
The trial enrolled 128 patients in cohort 1 and 91 patients in cohort 2 at multiple centers internationally.
The primary endpoint is confirmed objective response rate per blinded independent central review. Secondary endpoints include assessments of duration of response, disease control rate, progression-free survival, overall survival, safety and tolerability.
Padcev was approved by the U.S. Food and Drug Administration ( FDA ) in December 2019 and is indicated for the treatment of adult patients with locally advanced or metastatic urothelial cancer who have previously received a programmed death receptor-1 ( PD-1 ) or programmed death-ligand 1 ( PD-L1 ) inhibitor and a Platinum-containing chemotherapy before ( neoadjuvant ) or after ( adjuvant ) surgery or in a locally advanced or metastatic setting.
Urothelial cancer is the most common type of bladder cancer ( 90% of cases ), and can also be found in the urothelial cells that line the renal pelvis, ureter and urethra.
Globally, approximately 580,000 people will be diagnosed with bladder cancer in 2020, and bladder cancer will be attributed to approximately 210,000 deaths worldwide. ( Xagena )
Source: Seagen, 2020
The FDA ( Food and Drug Administration ) has granted accelerated approval to Monjuvi ( Tafasitamab-cxix, Tafasitamab ), a CD19-directed...
Ayvakyt for the treatment of adults with unresectable or metastatic PDGFRA D842V mutant gastrointestinal stromal tumors, approved by European Commission
The European Commission ( EC ) has granted conditional marketing authorization to Ayvakyt ( Avapritinib ) as a monotherapy for...
Polatuzumab Vedotin plus Venetoclax with Rituximab in relapsed / refractory diffuse large B-cell lymphoma
Polatuzumab vedotin ( Polivy ) combined with Rituximab ( MabThera ) has demonstrated activity and tolerability in a phase II...
Interim results of Loncastuximab tesirine associated with Ibrutinib in diffuse large B-cell lymphoma or mantle cell lymphoma
Patients with relapsed or refractory ( R/R ) diffuse large B-cell lymphoma ( DLBCL ) or mantle cell lymphoma (...
Opdivo plus Yervoy for patients with hepatocellular carcinoma previously treated with Sorafenib, FDA approved
Opdivo ( Nivolumab ) 1 mg/kg plus Yervoy ( Ipilimumab ) 3 mg/kg ( injections for intravenous use ) was...
The rapid spread of Coronavirus disease 2019 ( COVID-19 ) caused by severe acute respiratory syndrome coronavirus 2 ( SARS-CoV-2...
Rubraca as monotherapy treatment for patients with BRCA1/2-mutant, metastatic castration-resistant prostate cancer, treated with androgen receptor-directed therapy and a taxane-based chemotherapy
The FDA ( U.S. Food and Drug Administration ) has approved Rubraca ( Rucaparib ) tablets for the treatment...
Olaparib in patients with pancreatic cancer with BRCA1/2 inactivating mutations: results from TAPUR study
TAPUR ( Targeted Agent and Profiling Utilization Registry ) is a phase II basket study evaluating anti-tumor activity of targeted...
Efficacy and safety of Entrectinib in patients with NTRK-fusion positive solid tumors: updated integrated analysis
NTRK gene fusions lead to transcription of chimeric TRK proteins with overexpressed kinase function. Entrectinib ( Rozlytrek ) is a...